Compounds > 1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil
Page last updated: 2024-12-05

1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil is a synthetic compound that has attracted research interest due to its potential as a **therapeutic agent**. It's a derivative of uracil, a pyrimidine base found in DNA and RNA, with modifications that alter its biological activity.

**Here's why it's important for research:**

* **Potential anti-cancer activity:** Studies have shown that this compound exhibits cytotoxic activity against certain cancer cell lines, suggesting it could be developed into a new anti-cancer drug.
* **Possible antiviral activity:** Research indicates that 1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil may inhibit the replication of certain viruses. This opens the door for exploring its potential as an antiviral medication.
* **Investigating structure-activity relationships:** The modifications made to the uracil structure (ethoxymethyl, isopropyl, and phenylsulfanyl groups) are key to understanding how these changes affect its biological activity. Studying this compound can shed light on the crucial structural elements needed for therapeutic activity, aiding in the development of even more effective drugs.
* **New therapeutic targets:** Further research on this compound could reveal new pathways or mechanisms of action that could lead to the discovery of novel therapeutic targets for various diseases.

**Key points to remember:**

* This is a relatively new compound, and more research is needed to fully understand its properties, potential benefits, and safety profile.
* The exact mechanisms by which it exhibits its biological activity are still under investigation.

Overall, 1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil holds promise as a potential therapeutic agent, and ongoing research will be crucial to determine its ultimate clinical utility.

1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil : A pyrimidone that is uracil in which positions 1, 5, and 6 are substituted by ethoxymethyl, isopropyl, and phenylsulfanyl groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5495
CHEMBL ID38711
CHEBI ID40152

Synonyms (15)

Synonym
1-(ethoxymethyl)-6-(phenylsulfanyl)-5-(propan-2-yl)pyrimidine-2,4(1h,3h)-dione
i-epu, i-hepu
1-(ethoxymethyl)-5-isopropyl-6-phenylsulfanyl-pyrimidine-2,4-dione
5-isopropyl-1-ethoxymethyl-6-(phenylthio)uracil
1-etome-6phs-5-i-pr u
136160-32-2
chebi:40152 ,
CHEMBL38711 ,
1-ethoxymethyl-5-isopropyl-6-phenylsulfanyl-1h-pyrimidine-2,4-dione
bdbm50004119
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil
5-isopropyl-1-(ethoxymethyl)-6-(phenylthio)uracil
DTXSID70159711
1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylsulfanyl)pyrimidine-2,4(1h,3h)-dione
Q27120390
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.01200.00040.61539.7000AID200003; AID200009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.01200.00091.30738.0000AID199980
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID104274Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-11992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID1125802Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect2014European journal of medicinal chemistry, Apr-22, Volume: 77QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method.
AID200003Inhibition of HIV-1 reverse transcriptase at 37 degree Centigrade2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
AID235557Ratio of the EC50 against HIV-1 infected MT-4 cells and CC50 against mock infected MT-4 cells.1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID225321Concentration required to reduce viability of mock-infected MT-4 cells1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID200009Inhibitory concentration against HIV-1 reverse transcriptase1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
AID199980Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.58 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil: an anti-HIV agent; structure in first source. 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil : A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by ethoxymethyl, isopropyl, and 3,5-dimethylbenzyl groups, respectively.		1.9910pyrimidone
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.4120cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9810azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		2.0110acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		2.9340aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil: inhibits human HIV-1; structure given in first source		3.150
emivirine
emivirine: a non-nucleoside inhibitor of HIV-1 reverse transcriptase. emivirine : A pyrimidone that is uracil which is substituted at positions 1, 5 and 6 by ethoxymethyl, isopropyl, and benzyl groups, respectively. A non-nucleoside inhibitor of HIV-1 reverse transcriptase, emivirine was an unsuccessful experimental agent for the treatment of HIV.		2.6930pyrimidoneantiviral drug;
HIV-1 reverse transcriptase inhibitor
5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil
[no description available]		3.150
gw420867x
GW420867X: structure in first source		2.0110
e-ebu-dm
[no description available]		1.9910
12-hydroxynevirapine
12-hydroxynevirapine : A dipyridodiazepine that is nevirapine in which one of the hydrogens of the methyl group has been substituted by a hydroxy group. It is a metabolite of the anti-HIV drug, nevirapine.		2.4120aromatic primary alcohol;
cyclopropanes;
dipyridodiazepine		drug metabolite
r 82150
R 82150: structure given in first source; inhibits HIV-1 replication		2.0110
r-82913
R-82913: antiviral target on reverse transcriptase of HIV-1		2.0110
r 86183
[no description available]		2.0110
nsc 629243
NSC 629243: structure given in first source; an anti-HIV drug		2.0110
hby 097
HBY 097: a quinoxaline derivative		2.0110
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		2.0110
uc-781
[no description available]		2.0110
ly 73497
LY 73497: HIV-1 reverse transcriptase inhibitor; structure in first source		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials